

Clinical Eligibility Policy: Funding of Ceftriaxone

Please Note:

This is NOT intended as a Clinical Guideline for management in Primary Care

Rationale

Ceftriaxone is currently subsidised only if prescribed for:

- a dialysis or cystic fibrosis patient, or
- the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or
- the treatment of suspected meningitis in patients who have a known allergy to penicillin

Advice has been received from the Auckland Metro DHB Infectious Disease Clinical Directors. With regard use of Ceftriaxone outside hospital, this should be reserved only for treatment of ciprofloxacin-resisted gonorrhoea.

POAC POLICY

POAC will NOT fund the use of Ceftriaxone, outside of the Pharmac funding criteria, unless recommended by an Infectious Disease Consultant.

Consultant name and date of discussion must be documented in supporting clinical notes.